肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展

doi:10.11904/j.issn.1002-3070.2021.06.016

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (6): 568-571.doi: 10.11904/j.issn.1002-3070.2021.06.016

肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展

李响, 胡洋综述, 张清媛审校

哈尔滨医科大学附属肿瘤医院肿瘤内科(哈尔滨 150081)

收稿日期:2021-02-14 修回日期:2021-03-30 出版日期:2021-12-28 发布日期:2021-12-17
通讯作者: 张清媛,E-mail:0566@hrbmu.edu.cn
作者简介:李响,女,(1993-),硕士研究生,从事乳腺癌内科综合治疗的研究。

Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy

LI Xiang, HU Yang, ZHANG Qingyuan

Department of Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China

Received:2021-02-14 Revised:2021-03-30 Online:2021-12-28 Published:2021-12-17

摘要/Abstract

摘要： 随着免疫时代的到来,免疫治疗为乳腺癌提供了新的治疗方法。应用免疫检查点抑制剂(ICI)治疗乳腺癌已经在临床实践中取得了重大进展。但是,这种治疗药物只对少数患者有效,并且可能会导致免疫相关不良事件的发生,因此,必须通过使用相关的生物标志物来优化患者的治疗选择。最近,有研究证实肿瘤突变负荷(TMB)是一种可以预测乳腺癌免疫治疗疗效的新兴生物标记物。本文就TMB在乳腺癌患者免疫治疗疗效中的预测价值与应用现状等方面进行综述。

关键词: 乳腺癌, 肿瘤突变负荷, 免疫治疗, 免疫检查点抑制剂

Abstract: With the advent of the age of immunotherapy,breast cancer treatment has also opened a new treatment strategy.The application of immune checkpoint inhibitors(ICI)in the treatment of breast cancer has achieved remarkable success in clinical practice.However,because it is only effective for a small number of patients,immunotherapy may lead to the occurrence of immune-related adverse events.Therefore,the patient's treatment options must be optimized through the use of relevant biomarker.Recently,many studies have confirmed that tumor mutational burden(TMB)is an emerging biomarker that can predict the efficacy of breast cancer immunotherapy.The article reviews the predictive value and application status of TMB in immunotherapy for breast cancer patients.

Key words: Breast cancer, Tumor mutational burden, Immunotherapy, Immune checkpoint inhibitor

中图分类号:

R737.9

李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.

LI Xiang, HU Yang, ZHANG Qingyuan. Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy[J]. Journal of Practical Oncology, 2021, 35(6): 568-571.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.06.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I6/568

参考文献

1 国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会.中国晚期乳腺癌规范诊疗指南(2020版)[J].中华肿瘤杂志,2020,42(10):781-797.
2 Patience S,Chang X,Liu Z,et al.The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy[J].Eur J Pharmacol,2021,895:173867.
3 Zachary R,Chalmers CF,Connelly DF,et al.Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden[J].Genome Med,2017,9(1):1-14.
4 Yarchoan M,Hopkins A,Jaffee EM.Tumor mutational burden and response rate to PD-1 inhibition[J].N Engl J Med,2017,377:2500-2501.
5 Chang L,Chang M,Chang HM,et al.Microsatellite instability:a predictive biomarker for cancer immunotherapy[J].Appl Immunohistochem Mol Morphol,2017,26(2):15-21.
6 Chabanon RM,Pedrero M,Lefebvre C,et al.Mutational landscape and sensitivity to immune checkpoint blockers[J].Clin Cancer Res,2016,22(17):4309-4321.
7 Rooney MS,Shukla SA,Wu CJ,et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity[J].Cell,2015,160(1/2):48-61.
8 Cao D,Xu H,Xu X,et al.High tumor mutation burden predicts better efficacy of immunotherapy:a pooled analysis of 103078 cancer patients[J].Oncoimmunology,2019,8(9):1-12.
9 Schmid P,Adams S,Rugo HS,et al.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2018,379(22):2108-2121.
10 Emens LA,Molinero L,Adams S,et al.Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer:exploratory analysis of the phase III IMpassion130 trial[J].Ann Oncol,2020,31(4):360-361.
11 Karn T,Denkert C,Weber KE,et al.Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo[J].Ann Oncol,2020,31(9):1216-1222.
12 Yin Y,Li W,Huang X,et al.HER2 amplification is associated with higher tumor mutation burden in breast cancer[J].Ann Oncol,2018,29(8):146.
13 Park SE,Park K,Lee E,et al.Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer[J].Oncoimmunology,2018,7(8):e1466768.
14 Xu J,Bao H,Wu X,et al.Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer[J].Oncol Lett,2019,18(1):449-455.
15 Kawaji H,Kubo M,Yamashita N,et al.Comprehensive molecular profiling broadens treatment options for breast cancer patients[J].Cancer Med,2020,10(2):529-539.
16 Barroso SR,Jain E,Cohen O,et al.Prevalence and mutational determinants of high tumor mutation burden in breast cancer[J].Ann Oncol,2020,31(3):387-394.
17 Schnidrig D,Turajlic S,Litchfield K.Tumour mutation burden:primary versus metastatic tissue creates systematic bias[J].IOTECH,2019,4:8-14.
18 Lu S,Stein JE,Rimm DL,et al.Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade:a systematic review and meta-analysis[J].JAMA Oncol,2019,5(8):1195-1204.
19 James JL,Balko JM.Biomarker predictors for immunotherapy benefit in breast:beyond PD-L1[J].Curr Breast Cancer Rep,2019,11(4):217-227.

[1]	罗波, 张曲, 郑红梅, 梁新军, 周小妹, 吴新红. SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J]. 实用肿瘤学杂志, 2021, 35(6): 523-528.
[2]	史润泽, 李志高. 三阴性乳腺癌各亚型精准医疗策略研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 529-533.
[3]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[4]	于园园, 孟千皓, 王广雨. 胃癌免疫治疗困境与未来方向[J]. 实用肿瘤学杂志, 2021, 35(6): 552-556.
[5]	刘菲, 隋红. 基于肿瘤免疫微环境的肝癌分子分型研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 557-561.
[6]	周天虹, 顾秀瑛, 姚芳, 宋述铭. 乌鲁木齐市2014—2018年度乳腺癌筛查结果分析[J]. 实用肿瘤学杂志, 2021, 35(5): 391-395.
[7]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[8]	秦朝, 李江, 郑亚迪, 王飞, 曹巍, 许永杰, 余一雯, 赵亮, 于欣阳, 陈宏达, 任建松, 王勇, 李静, 李霓, 陈万青. 中国城市乳腺癌高危人群筛查依从性及其相关因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 291-296.
[9]	郭兰伟, 张韶凯, 刘曙正, 郑黎阳, 陈琼, 曹小琴, 孙喜斌, 张建功. 河南省城市地区乳腺癌筛查依从性及其影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(4): 307-313.
[10]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[11]	李钰莹, 张悦. Sirtuins在乳腺癌中作用机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 277-281.
[12]	提谦, 张清媛. CDK4/6抑制剂联合内分泌治疗晚期乳腺癌[J]. 实用肿瘤学杂志, 2021, 35(3): 287-290.
[13]	杨敏, 张娇燕, 段丹, 徐兵河. 乳腺癌照顾者研究的文献计量学及可视化分析[J]. 实用肿瘤学杂志, 2021, 35(2): 110-116.
[14]	王健宇, 张显玉, 庞达. Luminal A型乳腺癌新辅助化疗疗效的影响因素分析[J]. 实用肿瘤学杂志, 2021, 35(2): 131-136.
[15]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.

肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展

Research progress of tumor mutational burden as an emerging biomarker for breast cancer immunotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价